Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?
One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put United Therapeutics Corporation (UTHR - Free Report) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:
A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.
On this front, United Therapeutics has a trailing twelve months PE ratio of 13.7, as you can see in the chart below:
This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 stands at about 20.4. If we focus on the long-term PE trend, United Therapeutics’ current PE level puts it below its midpoint over the past five years, with the number having risen rapidly over the past few months.
Further, the stock’s PE also compares favorably with the broader industry’s trailing twelve months PE ratio, which stands at 49.7. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.
We should also point out that United Therapeutics has a forward PE ratio (price relative to this year’s earnings) of just 11.5, so it is fair to say that a slightly more value-oriented path may be ahead for United Therapeutics stock in the near term too .
Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.
Right now, United Therapeutics has a P/S ratio of about 2.5. This is a bit lower than the S&P 500 average, which comes in at 2.8x right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.
If anything, UTHR is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.
Broad Value Outlook
In aggregate, United Therapeutics currently has a Value Score of A, putting it into the top 20% of all stocks we cover from this look. This makes United Therapeutics a solid choice for value investors, and some of its other key metrics make this pretty clear too.
For example, the company’s P/CF ratio (another great indicator of value) comes in at 6.7, which is far lower than the industry average of 11.9. Clearly, UTHR is a solid choice on the value front from multiple angles.
What About the Stock Overall?
Though United Therapeutics might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth Score of C and a Momentum Score of C. This gives UTHR a Zacks VGM score — or its overarching fundamental grade — of B. (You can read more about the Zacks Style Scores here >>)
Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen four estimates go higher in the past sixty days compared to one lower, while the full year estimate has seen five down in the same time period.
This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has risen by 7.8% in the past two months, while the full year estimate has inched lower by 1%. You can see the consensus estimate trend and recent price action for the stock in the chart below:
This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.
United Therapeutics is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. Furthermore, a solid industry rank (among Top 34% of more than 250 industries) instills our confidence on the stock.
Nonetheless, over the past two years, the broader industry has clearly underperformed the broader market, as you can see below:
So, value investors might want to wait for estimates and analyst sentiment to turn around in this name first, but once that happens, this stock could be a compelling pick.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>